ClinicalTrials.gg
RecruitingNCT06183424Updated May 2, 2025

TDCS Stimulation After Covid-19 Infection

An interventional study of Transcranial Direct Stimulation in COVID-19, sponsored by Istanbul Medipol University Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in COVID-19 with a site in Turkey — 9 open to participants now, 11 under way, 3 of them phase 3. COVID-19 · Turkey.

Planned enrollment
110th of 178
50 · median 64
Started
2023
with 8 others
No phase
123 of 429
4 open now
Primary completion
2024-10
later than 6 of 10 live
Registered
390th of 429
by date

Among the 429 studies in COVID-19 with a site in Turkey, this one is the 110th largest by planned enrollment of the 178 interventional ones that give a count, is one of 9 that started in 2023, is one of 123 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 390th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 429 studies in COVID-19 with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in COVID-19 with a site in Turkey, or all of them as a file.
02

Study summary

In this study, the effects of bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) with active tDCS (transcranial direct stimulation/transcranial direct stimulation) on neurocognitive (memory and executive) functions in patients with Covid-19 infection and subjective cognitive complaints, as well as resting-state fMRI In the case of dfMRI, it is aimed to examine the default mode network (DMN) and parietal memory network (PMN) inter- and intra-network connectivity alterations and the hippocampal region connectivity alterations and contribute to the relevant literature.

Read the detailed description

The DMN is active when not engaged in a goal-oriented activity and at rest. Resting DNM is especially active when the mind is busy with introspective situations (Barkhof et al., 2014; Mak et al., 2017). Although the posterior parts of the DMN consisting of the posterior cingulate/precuneus and bilateral parietal cortex regions are associated with memory functions, memory functions are not unique to DMN and the parietal regions are not functionally homogeneous (Sestieri et al., 2011). At this point, a new network called the parietal memory network (PMN) was defined in a study by Gilmore (Gilmore et al., 2015). This network is a system that diverges from the posterior parts of the DMN and consists of the middle cingulate cortex, precuneus and inferior parietal lobule/angular gyrus structures and has overlapping regions with the DMN. This network appears to differ from the DMN in different types of recall memory functions. Accordingly, when recalling autobiographical information, DMN; PMN seems to be active in encoding and recall tasks related to recognition memory (McDermott et al., 2009; Chen et al., 2017; Nelson et al., 2013; Hu et al., 2016; Manenti et al., 2010; Kragel et al., 2016) . A double dissociation appears to occur between these two network systems in memory processes, and furthermore, the spacial proximity of PMN to the DMN suggests that some of the cognitive dysfunctions attributed to the DMN of these two systems are due to PMN. The fact that PMN is associated with memory encoding and recall functions even in different types of tasks (de-activity in perceiving new stimulus but being active in perceiving familiar stimulus) differentiates it from other network systems. Stimulation of the parietal region with repetitive transcranial magnetic stimulation (rTMS) resulted in improved visual recognition memory performance (Velioğlu et al., 2021).

The dorsolateral prefrontal cortex (DLPFC) is the central region associated with executive functions, and damage to this region is associated with difficulty in regulating behavioral responses, memory-retrieval, and inability to demonstrate appropriate motor behavior. Damages in this region are associated with cognitive loss in related areas (Liu et al., 2021; Brak et al., 2022). tDCS, on the other hand, stands out as a promising method for patients with Covid-19 infection and subjective cognitive complaints, and appears to act by modulating functional connectivity (Baptista, 2020; Linnhoff, 2023; Yulug B). Increased connectivity between the hippocampus and other DMN nodes such as the dorsal attention network, control, attention-attractiveness network, and sensori-motor networks was detected in fMRI with atDCS stimulation (Manenti et al., 2020; Meinzer et al., 2015). In this context, improvement in neurocognitive tests and changes in functional imaging can be detected with stimulation of the relevant regions of the cortex with tDCS in patients who have had Covid-19 infection and have subjective cognitive complaints. In patients with Covid-19 infection, stimulation of the relevant regions with tDCS resulted in improvement in cognitive functions such as working memory and cognitive control. (Baptista, 2020; Linnhoff, 2023; Yulug B,2023). At this point, DLPFC stimulation may also result in improved cognitive functions regarding encoding and recall.

From this point of view, in this study -based on the studies referenced in the text-, bilateral stimulation of the DLPFC region with anodal tDCS (atDCS) increased performance in neurocognitive abilities, especially memory and executive functions, in patients who had Covid-19 infection and had subjective cognitive complaints. The methodical mesh is shaped in the context of this template, hypothesizing that it will result in In addition, in the fMRI studies mentioned above, it is aimed to point out that tDCS stimulation increases the coherence between DMN networks and to examine the effect of tDCS stimulation on DMN network connectivity and connectivity with the hippocampal region with reference to the role of PMN in patients with Covid-19 infection and subjective cognitive complaints. From this point of view, the aim of this study is dorsolateral prefrontal cortex (DLPFC) active tDCS (transcranial direct stimulation/transcribed) in patients with covid-19 infection and subjective cognitive complaints.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Covid-19
  • tDCS
  • Cognitive function
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have received a positive value from the COVID-19 RT-PCR test in the last 60 days and turned negative
  • Being between the ages of 18-50
  • 21 days have passed since the disease onset date

Exclusion criteria

Exclusion Criteria:

  • Having any neurological or psychiatric disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Interventional

    Active tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.

    Procedure: Transcranial Direct Stimulation

  • Placebo comparator
    Sham

    For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.

    Procedure: Transcranial Direct Stimulation

Interventions

  • ProcedureTranscranial Direct Stimulation

    2 mA, 20 min, 5 days

06

What researchers measure

Primary outcomes

  1. Montreal cognitive assessment

    Cognition Test

    Time frame: Before Treatment / 1 month after treathment

  2. Cognition Test Material

    clock drawing test, digit range test, verbal fluency test, stroop test, trail making test

    Time frame: Before Treatment / 1 month after treathment

  3. NPI

    Cognition Test (Neuropsychiatric Inventory)

    Time frame: Before Treatment / 1 month after treathment

  4. Öktem Verbal Memory Processes Test

    Cognition Test

    Time frame: Before Treatment / 1 month after treathment

  5. Rey Complex Figure Test

    Cognition Test

    Time frame: Before Treatment / 1 month after treathment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2024, 12 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 12 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Dec 27, 2023
StartActual
Oct 1, 2023
Primary completionActual
Oct 1, 2024
CompletionEst.
Dec 1, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06183424
Collaborators
Alanya Alaaddin Keykubat University
Responsible party
Prof. Lutfu Hanoglu, MD (Prof. Dr. MD, Istanbul Medipol University Hospital) — Principal investigator
First posted
Dec 27, 2023
Start date
Oct 1, 2023
Primary completion
Oct 1, 2024
Completion
Dec 1, 2025 (estimated)
Last update
May 2, 2025

Study contacts

Cennet Sena Parlatan, phd Cand
Contact
cennet.parlatan@std.medipol.edu.tr
05077799164
Burak Yuluğ, Prof. DR. MD
study director · Alanya Alaaddin Keykubat Üniversitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion